Tirzepatide: Revolutionary Drug in Management of “Diabesity”

##plugins.themes.academic_pro.article.main##

Vansh Chouhan
Simran Spal
Rakesh Kumar

Abstract

Tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist has recently been approved by FDA for type 2 diabetes in adults as a single dose weekly. Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity. Tirzepatide is also under evaluation for treatment of non-alcoholic steatohepatitis, heart faialure and obstructive sleep apnea.

##plugins.themes.academic_pro.article.details##

How to Cite
Chouhan, V., Spal, S., & Kumar, R. (2022). Tirzepatide: Revolutionary Drug in Management of “Diabesity”. International Journal of Medical and Dental Sciences, 11(2), 2046–2050. https://doi.org/10.18311/ijmds/2022/636

References

  1. Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: A bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011; 60:3103-9. https://doi.org/10.2337/db11-0979 PMid:21984584 PMCid:PMC3219 957
  2. Yip RG, Boylan MO, Kieffer TJ, Wolfe MM. Functional GIP receptors are present on adipocytes. Endocrinology. 1998; 139:4004-7. https://doi.org/10.1210/endo.139.9.6288 PMid:9724057
  3. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018; 18:3-14. https://doi.org/10.1016/j.molmet.2018.09.009 PMid:30473097 PMCid: PMC6308032
  4. A study of Tirzepatide (LY3298176) in participants with type 2 diabetes not controlled with diet and exercise alone (SURPASS-1)- study results [Internet]. A study of tirzepatide (LY3298176) in participants with type 2 diabetes not controlled with diet and exercise alone- Study ResultsClinicalTrials.gov. [cited 2022 Jul11]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03954834
  5. A study of tirzepatide (LY3298176) versus semaglutide once weekly as add-on therapy to metformin in participants with type 2 diabetes (SURPASS-2)- study results [Internet]. A study of tirzepatide (LY3298176) versus semaglutide once weekly as add-on therapy to metformin in participants with type 2 diabetes- Study Results- ClinicalTrials.gov. [cited 2022 Jul11]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03987919?view=results
  6. A study of tirzepatide (LY3298176) versus insulin degludec in participants with type 2 diabetes (SURPASS-3)- study results [Internet]. A study of tirzepatide (LY3298176) versus insulin degludec in participants with type 2 diabetes - Study Results - ClinicalTrials.gov. [cited 2022 Jul11]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03882970?view=results
  7. A study of tirzepatide (LY3298176) once a week versus insulin glargine once a day in participants with type 2 diabetes and increased cardiovascular risk (SURPASS-4)study results [Internet]. A study of tirzepatide (LY3298176) once a week versus insulin glargine once a day in participants with type 2 diabetes and increased cardiovascular risk- Study Results - ClinicalTrials.gov. [cited 2022Jul11]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03730662?view=results
  8. A study of tirzepatide (LY3298176) versus placebo in participants with type 2 diabetes inadequately controlled on insulin glargine with or without metformin (SURPASS-5) study results [Internet]. A study of tirzepatide (LY3298176) versus placebo in participants with type 2 diabetes inadequately controlled on insulin glargine with or without metformin - Study Results - ClinicalTrials.gov. [cited 2022Jul11]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT04039503?view=results
  9. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck
  10. MC, Stefanski A. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022 Jun 4. https://doi.org/10.1056/NEJMoa2206038 PMid:35658024

Most read articles by the same author(s)